Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Obrixtamig · BI-764532

Bispecific antibody · Immune activation, directed at delta-like protein 3 (DLL3) and CD3 (CD3E) · developed by Boehringer Ingelheim

Phase 1/2 Most advanced trial
2 Registered trials

What is Obrixtamig?

Obrixtamig is a bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on cytotoxic T-lymphocytes. By bringing these T cells to DLL3-expressing cells, it triggers T-cell-mediated death of those tumor cells. It is studied in small cell lung cancer and related neuroendocrine lung and extrapulmonary carcinomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BI-764532
Drug type
Bispecific antibody
Targets
delta-like protein 3 (DLL3), CD3 (CD3E)
Mechanism
Immune activation, directed at delta-like protein 3 (DLL3) and CD3 (CD3E)
Pathways
Notch signaling, T-cell mediated cytotoxicity
Therapy area
Oncology
Developer
Boehringer Ingelheim
In trials of
BNTX, ZLAB
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
Y09G7LIC1A

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07707895 Phase 1/2 Small Cell Lung Cancer Recruiting ZLAB
NCT07843940 Phase 1/2 Extensive-stage Small Cell Lung Carcinoma Recruiting BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Small Cell Lung CancerExtensive-stage Small Cell Lung CarcinomaLarge Cell Neuroendocrine Lung CarcinomaSmall Cell Lung Cancer

Other drugs acting on DLL3 / CD3E

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.